Given the lack of compelling evidence supporting routine surveillance for patients with DLBCL and FL, all patients should be counseled regarding the potential risks associated with routine surveillance prior to initiating a follow-up program with regularly scheduled CTs. PET/CT should not be utilized in routine follow-up except for patients whose site of disease cannot be reliably detected on a CT (ie, bony sites of disease).

* CT and/or PET should be considered as clinically appropriate at any time that relapse is suspected based on clinical signs or symptoms.

†Imaging modality to be used during follow-up for Burkitt lymphoma and PTCL are not specified in the 2014 American College of Radiology or NCCN guidelines.